September 17, 2026
With a Capital Markets Day days away and the stock near a two-year low, traders need the strategy numbers, not the new name.
On September 14, 2026, Novo Nordisk dropped “Nordisk” from its public identity, rebranding as simply “Novo” under the tagline “Lasting Health Starts Now.” The legal name stays Novo Nordisk A/S. The cultural framework, called “The Novo Way,” is built around four operating principles: Customer Obsession, Competitiveness, Clarity, and Care & Integrity. Strategy details follow at a Capital Markets Day in London on September 21.
Hidden in Tesla’s Filing: A $12 Billion “Super Startup”
Pull up Tesla’s most recent SEC filing. Page 5.
And you’ll see a single line showing $12 billion in revenue from a brand-new “super startup” Elon Musk has been quietly incubating inside Tesla.
This new “super startup” has nothing to do with cars or robots or space or AI…
But it sits at the center of what Blackstone calls “a $23 trillion investment opportunity.”
And on October 21, Elon is expected to pull back the curtain and reveal exactly what he’s building.
But Adam O’Dell already knows… and he reveals it all in this urgent video.
BMO Capital Markets was blunt in a Sunday note: “One launch, in one country, does not a turnaround make.” That is the real framing traders should carry into next week. The rebrand is a signal. The September 21 numbers are the signal that matters.
Where the Stock Actually Sits
NVO closed at $43.45 on September 14, inside a 52-week range of $35.12 to $64.16. That represents a decline of about 68% from the June 25, 2024 closing high of $135.66. The forward P/E has compressed to roughly 13x against a drug-manufacturer industry median closer to the mid-teens, and the five-year average forward multiple was in the mid-20s. The valuation gap is real; so is the earnings pressure behind it.
Q2 2026 adjusted sales grew 7% at constant exchange rates, with adjusted operating profit up 11% at CER. Full-year 2026 guidance calls for adjusted sales growth of 0% to -6% at CER. Gross margin fell to 78.2% from 82.7% a year ago, with Wegovy injectable sales down 22% year over year. The restructuring that began in September 2025, targeting roughly 9,000 job reductions and DKK 8 billion in annualized savings by end of 2026, is the operational floor the company is building from.
971 Trades. One Surprisingly Simple Approach.
Five years. Bull markets, selloffs, sideways stretches – and 971 trades along the way. Dave Aquino’s Ultimate Income System focuses less on predicting the next big move and more on finding consistent trading opportunities. His new report explains the approach, why it works differently, and what most traders may be missing.
The One Bright Spot and the Competitive Threat Behind It
The Wegovy pill has been the standout. Launched in the U.S. on January 5, 2026, it has now exceeded 5 million U.S. prescriptions since launch. In the UK, regulators have approved the semaglutide (Wegovy) tablet, but broad NHS access still depends on NICE review. Germany is scheduled next. The OASIS 4 readout has been cited by the company as supporting up to 16.6% mean weight loss. Recent tracking has put the obesity market split at roughly 40% for Novo and about 60% for Eli Lilly.
Lilly’s oral GLP-1, orforglipron (Foundayo), is already FDA-approved, which pulls forward the competitive clock versus a “someday” risk. Amycretin, Novo’s dual GLP-1/amylin receptor agonist (also referred to as zenagamtide in some disclosures), showed up to 14.6% weight loss over 36 weeks in Phase 2. The company has said it plans to initiate Phase 3 programs in 2026, positioning it as a potential bridge beyond semaglutide patents that begin expiring in the early 2030s.
What Traders Are Watching
The stock sits below its 50-day simple moving average near $47.89, with the 52-week low at $35.12 functioning as the downside reference. Morgan Stanley downgraded NVO to Underweight on September 11, citing market share loss and the patent cliff. The average 12-month analyst price target is $47.22, implying roughly 8.7% upside from the September 14 close. HSBC moved its target higher on September 10.
The Oil “Red Zone” Is Coming. It Could Wipe You Out.
The International Energy Agency is warning of a coming “red zone” in the oil markets, and it could be brutal for the U.S. economy. But if you see it coming, you could “skim” off big bucks.
Three scenarios frame the range. Bull case: September 21 reveals concrete cost targets and an amycretin Phase 3 timeline that expands the addressable window beyond semaglutide; the stock reclaims the $50-$55 range as the multiple re-rates toward 16x. Base case: Capital Markets Day restates 2026 guidance, oral Wegovy volumes grow steadily, and NVO consolidates between $40 and $48 through year-end as the market waits for 2027 earnings inflection. Bear case: Orforglipron’s faster-than-expected uptake and contracting pricing power compress Novo’s margins more than modeled, Medicaid coverage cuts bite harder than expected, and NVO revisits the $35 area on further guidance reductions.
Preparation over prediction: what September 21 discloses about margin recovery, amycretin timelines, and geographic Wegovy pill rollout is the data that resets this stock, not the logo.
